Cosmetic outcomes after breast-conserving therapy may vary by race

Key points
- Despite similar results on objective assessments, "It appears that there is a difference in the perception of cosmetic outcomes between Caucasian and African-American patients," according to the study led by ASPS Member Surgeon Dr.
- The pilot study included 21 women undergoing BCT for breast cancer: 10 African-American and 11 Caucasian women.
- However, there was significant variation in subjective outcomes, with lower scores for African-American women.
- Plastic and Reconstructive Surgery - Global Open (PRS GO) is a companion journal to the American Society of Plastic Surgeons' flagship publication, Plastic and Reconstructive Surgery.
As perceived by both patients and doctors, the cosmetic results after "lumpectomy" for breast cancer differ for African-American versus Caucasian women, suggests a pilot study in the Plastic and Reconstructive Surgery - Global Open®, the official open-access medical journal of the American Society of Plastic Surgeons (ASPS).
Despite similar results on objective assessments, "It appears that there is a difference in the perception of cosmetic outcomes between Caucasian and African-American patients," according to the study led by ASPS Member Surgeon Dr. Robert D. Galiano of Northwestern University Feinberg School of Medicine. They call for further studies using validated assessment tools to help in optimizing breast appearance for women undergoing breast-conserving therapy (BCT).
Study Finds Similar Objective Outcomes By Race…
The pilot study included 21 women undergoing BCT for breast cancer: 10 African-American and 11 Caucasian women. Breast-conserving therapy combines lumpectomy or other limited surgery, as an alternative to mastectomy. Surgery is typically followed by radiation therapy to reduce the risk of recurrent breast cancer.
All women underwent detailed, "multimodal" assessments of their cosmetic outcomes. This included objective measurements of breast volume and symmetry, based on three-dimensional photographic analysis.
In addition, a newly developed questionnaire was used for subjective ratings of the cosmetic outcomes after BCT. Independent rankings of the appearance of the nipple, overall breast shape, scarring, and skin were made by the patients as well as by a plastic surgeon, a breast oncologic surgeon, and a trained research assistant.
All objective measurements were similar between groups. The average volume of the breast undergoing lumpectomy was somewhat smaller (by about 100 cc) than that in the untreated breast, with no significant difference between African-American versus Caucasian patients.
…But Significant Differences in Subjective Ratings
However, there was significant variation in subjective outcomes, with lower scores for African-American women. Patients and health care professionals both rated breast symmetry and appearance lower in African-American compared to Caucasian patients.
Nipple appearance and breast shape ratings were fairly consistent between patients and various health care professionals. However, there was wider variation when it came to scar appearance ratings.
Breast-conserving therapy is an important option for breast cancer treatment, with the potential for better final appearance of the breast. Some studies have reported racial/ethnic differences in cosmetic outcomes, including a lower rate of "good or excellent" outcomes in African-American women.
Written and revised by
David Cohen, M.D.
Our doctors write and review articles for accuracy and keep them up to date.
health.am provides general information, not medical advice. Always consult a qualified health professional about your own health.
Explore health topics
More in this topic
Cancer →
NewsBenefit of endocrine therapy in elderly women with low risk hormone receptor positive breast cancer?
Default Text Formatting for This Field Default Text Formatting for This Field
17 September 2014
NewsNovel Immunotherapy Vaccine Decreases Recurrence in HER2 Positive Breast Cancer Patients
A new breast cancer vaccine candidate, (GP2), provides further evidence of the potential of immunotherapy in preventing disease recurrence. This is especially the case for high-risk patients when it is combined with a…
6 September 2014
NewsYale researchers identify targets for immunotherapy in early-stage breast cancer
Yale Cancer Center researchers used a new molecular analysis tool to accurately detect the level of an important target for immunotherapy in early-stage breast cancers. The diagnostic test, using RNAScope, measures the…
19 July 2014


